Intangible Assets and Royalty Agreement (Details) - USD ($)			3 Months Ended
		Jan. 29, 2007	Mar. 31, 2016	Mar. 31, 2015	Jan. 13, 2016	Dec. 31, 2015	Jan. 05, 2011
Finite-Lived Intangible Assets [Line Items]
Total			$ 39,385,000			$ 15,627,000
Less Accumulated amortization			(5,675,000)			(4,864,000)
Net			33,710,000			10,763,000
Amortization of intangible assets			810,000	$ 233,000
Estimated future amortization expense [Abstract]
2016	[1]		2,434,000
2017			3,156,000
2018			2,766,000
2019			2,766,000
2020			2,091,000
Thereafter			18,489,000
Net book value			$ 31,702,000
Licenses and permits
Finite-Lived Intangible Assets [Line Items]
Weighted average amortization lives			7 years
Gross carrying value	[2],[3]		$ 1,769,000			1,009,000
Licenses and permits | Shriners Hospitals for Children and University of South Florida Research Foundation, Inc.
Finite-Lived Intangible Assets [Line Items]
Acquisition price		$ 996,000
Maximum time of approval		30 days
Fair value of earn - out			$ 200,000
Contingent royalty to be paid to licensor (percent)			3.00%
Annual royalty payment		$ 50,000
Licenses and permits | Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross carrying value							$ 13,000
Patents & Know How
Finite-Lived Intangible Assets [Line Items]
Weighted average amortization lives			19 years
Gross carrying value	[3]		$ 18,233,000			8,001,000
Patents & Know How | Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross carrying value							7,690,000
Finite-Lived intangible assets, costs			$ 1,000
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted average amortization lives			13 years
Gross carrying value	[3]		$ 12,681,000			3,761,000
Customer relationships | Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross carrying value							3,761,000
Tradenames & Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite lived	[3]		$ 2,008,000			1,008,000
Tradenames & Trademarks | Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite lived							1,008,000
Non compete agreements
Finite-Lived Intangible Assets [Line Items]
Weighted average amortization lives			4 years
Gross carrying value			$ 2,700,000			0
In Process Research & Development
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite lived	[3]		25,000			25,000
In Process Research & Development | Surgical Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite lived							$ 25,000
Patents in Process
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite lived	[4]		1,969,000			$ 1,823,000
Stability Biologics, LLC
Finite-Lived Intangible Assets [Line Items]
Fair value of earn - out			$ 33,240,000		$ 33,240,000
Stability Biologics, LLC | Licenses and permits
Finite-Lived Intangible Assets [Line Items]
Gross carrying value					760,000
Stability Biologics, LLC | Patents & Know How
Finite-Lived Intangible Assets [Line Items]
Gross carrying value					10,230,000
Stability Biologics, LLC | Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross carrying value					8,920,000
Stability Biologics, LLC | Tradenames & Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross carrying value, indefinite lived					1,000,000
Stability Biologics, LLC | Non compete agreements
Finite-Lived Intangible Assets [Line Items]
Gross carrying value					$ 2,700,000

[1] Estimated amortization expense for the year ending December 31, 2016, includes only amortization to be recorded after March 31, 2016.

[2] On January 29, 2007, the Company acquired a license from Shriners Hospitals for Children and University of South Florida Research Foundation, Inc. in the amount of $996,000. Within 30 days after the receipt by the Company of approval by the FDA allowing the sale of the first licensed product, the Company is required to pay an additional $200,000 to the licensor. Due to its contingent nature, this amount is not recorded as a liability. The Company will also be required to pay a royalty of 3% on all commercial sales revenue from the licensed products. The Company is also obligated to pay a $50,000 minimum annual royalty payment over the life of the license.

[3] On January 5, 2011, the Company acquired Surgical Biologics, LLC. As a result, the Company recorded intangible assets for Customer & Supplier Relationships of $3,761,000, Patents & Know-How of $7,690,000, Licenses of $13,000, Tradenames & Trademarks of $1,008,000 and In-Process Research & Development of $25,000. For the three months ended March 31, 2016, approximately $1,000 of costs associated with patents granted during the period were capitalized and included in Patents & Know-How subject to amortization.

[4] Patents in Process consist of capitalized external legal and other registration costs in connection with internally developed tissue-based patents that are pending. Once issued, the costs associated with a given patent will be included in Patents & Know-How under intangible assets subject to amortization.